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Summary It is not yet clear whether some polymorphic variants of the Ha-ras-1 gene confer genetic
predisposition to cancer. However, recent data on myelodysplasia and lung cancer are controversial. To
clarify this point, 62 colorectal adenocarcinoma patients were examined for the Ha-ras-I gene restriction
fragment length polymorphism and results were compared with those of 108 healthy blood donors. No Ha-
ras-1 polymorphic variants specifically associated with the cancer patients were detected. However, a specific
genotype was significantly more frequent in the healthy donors than in the cancer patients (16% versus 5%),
suggesting an interaction between the two alleles of the gene.
Tumours of different histological types, both in human and blood donors (HBD) by restriction fragment length poly-
in animal systems, have been found to be associated with ras morphism (RFLP).
proto oncogenes activated by mutation and/or overexpression.
Activation by mutation has been demonstrated by the DNA Materials and methods
transfection technique and ascribed to somatic single base
mutations in the region of the 12th and/or 61st codons Subjects
(McGrath et al., 1984; Sweet et al., 1984; Gibbs et al., 1984).
These mutations change the primary structure of the p21 Colorectal adenocarcinoma tissue samples and peripheral
codified proteins, conferring on them transforming blood leucocytes (PBL) were obtained during surgery from
properties. However, mutationally activated ras genes appear 62 CCP. Normal PBL were obtained from 108 HBD at the
to be present in only a minority of naturally occurring Transfusion Center of the Pordenone Hospital and used as
human tumours (Slamon et al., 1984; Fujita et al., 1984). controls to determine frequency of the Ha-ras-l alleles in a
Activation by overexpression was demonstrated by Chang et normal population.
al. (1982), who transfected the human Ha-ras-I protoonco-
gene linked to viral LTR in NIH/3T3 cells. In this configura- DNA extraction
tion, the viral LTR enhances many fold the production of
the normal human p21 protein in the recipient cells and DNA was extracted from carcinoma samples, from PBL of
confers transforming properties on them. CCP, and from PBL of HBD according to the method of
Although it is difficult to demonstrate that ras proto- Wong-Staal et al. (1979).
oncogene overexpression confers transforming properties in
natural systems, p21 overexpressions have been detected in a Probe DNAs
large number of premalignant and malignant human
tumours (Spandidos & Kerr, 1984). Plasmid p344 carrying the normal Ha-ras-1 human gene
It is not currently known how ras gene expression is (Pulciani et al., 1982) was grown and purified by standard
controlled. However, at least for the Ha-ras-1 proto- methods. Two fragments were used to study the poly-
oncogene, experimental data from Krontiris et al. (1985) morphism of the VTR region: (a) the BamHI 6.6 Kilobase
seem to indicate that a repetitive genomic region called the pair (Kb) fragment encoding the complete Ha-ras-1 sequence
variable tandem repetition region (VTR) could have an plus the VTR region, and (b) the 1 Kb MspI and HpaII
important function in Ha-ras-I gene expression. fragment encoding the VTR region. The p344 fragments
Golfarb et al. (1982) stated that the Ha-ras-I gene is were purified by preparative agarose electrophoresis and
highly polymorphic in a human population. This poly- the low melting agarose procedure. Both probes were
morphism, first detected by the BamHI restriction enzyme, 32P labelled by nick translation at specific activity
was ascribed by Capon et al. (1983) to changes in the >108cpm g-1.
number of repeat units that form the VTR region. This was
recently confirmed by Pierotti et al. (1986) by the use of Southern analysis
TaqI restriction enzyme mapping. Ha-ras-1 alleles are
inherited in a Mendelian fashion and do not arise de novo in Genomic DNAs (1Ougg) were digested to completion with the
tumours (Krontiris et at., 1985; Pierotti et at., 1986). They appropriate restriction enzymes, as specified by the
therefore supply a potentially useful tool for genetic analysis commercial supplier. Digested DNAs were subjected to
of cancer susceptibility conferred by specific alleles of the electrophoresis on horizontal 0.7% or 1.0% (w/v) agarose
Ha-ras-l gene (Krontiris et at., 1985). gels in 40mM Tris acetate, 20mM Na acetate and 2mM
To ascertain whether specific Ha-ras-l VTR conforma- EDTA buffer pH 7.6. Denatured DNA fragments were
tions confer genetic predisposition to the development of blotted onto a Gene Screen Plus (New England Nuclear,
colorectal cancer, we analyzed the distribution of Ha-ras-l1 Firenze, Italy) following standard procedures, as described
alleles in 62 colorectal cancer patients (CCP) and 108 healthy by Southern (1975).
Hybridization, washing and autoradiography were carried
out as described by Ceccherini-Nelli et at. (1982) HindIII-
Correspondence: L. Ceccherini-Nelli. digested ADNA and HaeIII-digested Xx 174 DNA were used
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Results alleles: some MspI and HpaII VTR-containing fragments
were only slightly reduced in size by TaqI digestion (Figure
Variation in the length of the VTR region generates RFLP of 2, samples 1-II-III-IV and the 2Kb fragment of sample V)
the Ha-ras-l gene whereas other MspI and HpaII VTR-containing fragments
In human genomic DNA, BamHl restriction enzyme
were cleaved by the TaqI enzyme into small fragments of
restriction fragments containing the complete 800 and 650bp (Figure 2, sample V fragment of 2.5Kb).
nerat
e s r r * r Presumably, three fragments were produced, two of which functional Ha-ras-1 gene. These fragments range in size from coirae inorgl.Rsut'hrfr.idctdta
6.6 to 8.2 Kb (Figure la) owing to the variation in length of humian aa alleles could berdiide intocthe mai
the VTR region of the gene. This is clearly demonstrated by . . . typ~tes as de icted in Fi ure 3. Type A represents the digestion of the human genomic DNAs by the two isoschizo- yp g yp
mers Mspl and Hpall. whichcleavetheHaras genmolecular asset of the more abundant Ha-ras-I allele
mers Mspg and H wc erae
t Hras-l gen just characterized by the shorter VTR region; type B includes outsideath VTRregI and genete a resri tionfaget those alleles characterized by amplification of the VTR
trom eachHrasponllle wHo lenthistion ato region; type C is characterized by unique amplification of
the VTR region with concomitant reiteration of Tani sites not shown).
Sequential digestions of genomic DNAs, first with the inside the VTR amplified region.
MspI and HpaII restriction enzymes and subsequently with
the TaqI restriction enzyme, followed by hybridization with IV V
the 1 Kb VTR-specific probe showed two different
2 I
2 I V
behaviours of the VTR region from different Ha-ras-I 1 2 1 2 1 2 1 2 1 2
a a b c d e f
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Figure 2 Southern analysis of representative genomic DNAs
from colonic adenocarcinoma and healthy blood donors digested
- ~~~~~~with Hpall and MsplI lane 1, and Hpall and Mspl plus Taql,
lane 2, probed with the 1 Kb VTR-specific fragment of the p344
~~~ I ~~~~~~~~~~Ha-ras-lI gene.
Genotype and allele distribution in patient and control group
b a b c d e f g h i I RFLP was generated in normal PBL DNAs and in tumoral _ ~~~DNAs by digestion with BamHI and Taql restriction
4.2 enzymes and resolved by molecular hybridization with the
4.0 BamHl fragment of the p344 plasmid. Digestion by BamHl
3.7 gave fragments which ranged in size from 6.6. to 8.2Kb and
which we separated into four classes of 6.6, 7.2, 7.8 and
3.0 8.2 Kb. Despite some heterogeneity, we did not separate
BamHI alleles into more classes due to difficulty in
2.5 ascertaining whether variations in the range of 0.1-0.2Kb
2.3 were due to effective differences in dimensions or to
experimental variability. However, BamHI mapping was
useful to indicate homozygosity or heterozygosity of the
genotypes and to confirm TaqI restriction maps (Table I).
TaqI digestion of the Ha-ras-l gene generated invariable and
variable fragments (Figure lb). The variable fragments that
_ ~~~~~~~~~~~~~~contained the VTR region ranged in size from 2.3 to 4.2 Kb.
_ ~~~~~~~~~~~~~The VTR-containing fragment of 2.3 Kb comigrated with the
f i !i _ _ - | ~~~~~~~~~~~~major invariable fragment of 2.3Kb (Figure 1b, lanes f, h, 1).
Howelver,itacold beidnentS ified by its association with two
0 ~~~~~~~~~~~065 BamHI restriction maps (Table I).
Figure 1 Southern analysis of representative genomic DNAs variable fragments: 2.3 (plus 0.8 and 0.65Kb), 2.5, 2.7, 2.9,
from colonic adenocarcinoma patients and healthy blood donors 3.0, 3.7, 4.0 and 4.2Kb, with some degree of microhetero-
digested with (a) BamHI and (b) TaqI restriction enzymes, geneity within each class. TaqI restriction maps were much
probed with the p344 Ha-ras-l gene. more resolvable than the ones obtained with BamHI. WeHa-ras-I RFLP IN COLON ADENOCARCINOMA 3
Table I Ha-ras genotype frequencies
Size of Size of Colon
BamHIfragments TaqI fragmentsa adeno- Healthy
(Kb) (Kb) carcinoma blood
patients donors Total
Genotype a b a b (No.) (No.) (No.) PC
1 6.6 6.6 2.5 2.5 28 (45)b 42 (39) 70 (41)
II 6.6 6.6 2.5 2.7 1 (2) 3 (3) 4 (2)
III 6.6 6.6 2.5 4.2d 0 (0) 2 (2) 2 (1)
IV 6.6 7.2 2.5 3.0 3 (5) 17 (16) 20 (12) 0.034
V 6.6 7.2 2.5 2.9 1 (2) 0 (0) 1 (0.6)
VI 6.6 7.2 2.7 3.0 1 (2) 0 (0) 1 (0.6)
VII 6.6 7.8 2.5 3.7 7 (11) 16 (15) 23 (14)
VIII 6.6 7.8 2.5 2.3+0.8+0.65 8 (13) 16 (15) 24 (14)
IX 6.6 7.8 2.5 4.0d 0 (0) 1 (1) 1 (0.6)
X 6.6 7.8 3.7 4.2d 1 (2) 0 (0) 1 (0.6)
XI 6.6 7.8 4.2d 2.3+0.8+0.65 0(0) 1(1) 1(0.6)
XII 6.6 8.2 2.5 2.5 1 (2) 0 (0) 1 (0.6)
XIII 7.2 7.2 3.0 3.0 2 (3) 0 (0) 2 (1)
XIV 7.2 7.8 3.0 3.7 1 (2) 1 (1) 2 (1)
XV 7.2 7.8 3.0 2.3+0.8+0.65 1 (2) 3 (3) 4 (2)
XVI 7.8 7.8 3.7 3.7 0 (0) 3 (3) 3 (2)
XVII 7.8 7.8 3.7 2.3+0.8+0.65 4 (6) 1 (1) 5 (3)
XVIII 7.8 7.8 2.3+0.8+0.65 2.3+0.8+0.65 3 (5) 2 (2) 5 (3)
62 108 170
aOnly the variable restriction fragments appear for TaqI restriction enzyme digestion; bFigures in parentheses are
percentages of the total; 'p was calculated by the chi square test; dTaql variable restriction fragment whose size does
not correspond to the BamHI restriction fragment size.
therefore classified Ha-ras-I alleles in accordance with TaqI- relevant restriction sites could generate the observed dis-
generated fragments. crepancies.
Table I shows that all the Ha-ras-I genotypes, given by Table II gives Taql generated allele frequencies in CCP
BamHI and TaqI restriction enzymes both in normal and and HBD populations. Statistical analysis performed by the
patient populations, were in accordance with the previously chi square test on allele frequencies shown in Table II did
depicted model based on the amplification of the VTR not indicate that any allele was significantly more frequent in
region as the origin of the different polymorphic variants of CCP than in HBD. In contrast the genotype type IV (Table
the gene (Figure 3). Only 5 out of 340 alleles analyzed I) was significantly more frequent in HBD than in CCP; it
generated restriction fragments that did not follow the appeared in 17/108 HBD versus 3/62 CCP x2 =4.48;
proposed scheme. We supposed that mutations at the P=0.034.
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Figure 3 Schematic representation of the Ha-ras-l cloned T24-C3 gene (Pulcianai et al., 1982) is shown in type A: Black boxes
represent exons and white boxes the VTR region. Type B: Alleles generated by amplification of the VTR region. Type C: Alleles
generated by amplification of the VTR region plus reiteration of TaqI restriction sites within the VTR region.4 L. CECCHERINI-NELLI et al.
Table II Ha-ras-1 allele frequencies
Size of Colon Healthy
TaqIfragment adenocarcinoma blood
(Kb) patients donors Total
2.5 78 (63)' 139 (64) 217 (64)
2.3+0.8+0.65 19 (15) 25 (12) 44 (13)
3.7 13 (10) 24 (11) 37 (11)
3.0 10 (8) 21 (10) 31 (9)
2.7 2 (2) 3 (1) 5 (1)
2.9 1 (1) 0 (0) 1 (0.3)
4.2 1 (1) 3 (1) 4 (1)
4.0 0 (0) 1 (0.4) 1 (0.3)
124 216 340
The table refers to allele frequencies and not to individuals
carrying the various alleles.
aFigures in parentheses are percentages of the totals.
Finally, analysis of Ha-ras-1 RFLP in matched DNA
samples derived from tumour and PBL of single patients
showed identical restriction patterns by several restriction
enzyme digestions.
In no case was evidence found of an allele lost in colon
carcinoma tumoral DNA.
Discussion
The Ha-ras-I protooncogene is highly polymorphic in a
human population, mainly due to a hypervariability in the
length of the VTR region localized at about 1.5Kb from the
the 3' terminus of the gene (Capon et al., 1983). No defined
biological properties have been associated with the VTR
regions. However, the characteristic of this region (that is
28 bp consensus sequence reiterated 29 times in the p344
gene) suggests that the VTR region could have an important
function in the regulation of the expression of this gene. This
hypothesis is supported by the report of Krontiris et al.
(1985), who found that EJ-ras subclones lacking the VTR
region are expressed 5- to 10-fold less than the original
clone. Moreover, Ishii et al. (1986) reported that VTR acts
as an enhancer element of the Ha-ras-I gene and that
specific conformations of this region have stronger enhancer
activity.
Ha-ras-I alleles are inherited in a Mendelian fashion. This
circumstance has been utilized by different authors to
ascertain genetic susceptibility to cancer diseases conferred
by this gene.
Krontiris et al. (1985) described the association of rare
Ha-ras-I alleles with tumours of different histological types.
Thein et al. (1986) reported the lack of an association
between Ha-ras-l alleles and myelodysplasia. Heighway et al.
(1986) found a significant association between a specific Ha-
ras-l allele and non-small cell carcinomas of the lung when
compared to unaffected controls and small cell carcinoma
patients.
In the present report we analyzed Ha-ras-1 gene RFLP in
62 CCP and 108 HBD. Since the median age of the control
group was lower than the age at which colon cancer becomes
clinically evident, we concluded that allele distribution in our
control group represented that present in a general popu-
lation. The data obtained from the present study indicated
that no significant association exists between any Ha-ras-I
allele and predisposition to colorectal cancer. In fact, the
observed frequencies of the four most abundant alleles were
almost identical in patient and control groups. As regards
the rare alleles, it is impossible, by this study, to define their
influence in this pathology due to their very low frequency
observed in the patient group. In contrast, our data seem to
suggest that the genotypic asset at the Ha-ras-1 locus could
have some influence in determining resistance to the
development of colon cancer. In fact, the type IV genotype
appears to be more frequent in the HBD than in the CCP
group. The meaning of this finding is not yet clear. However,
it could indicate that some interaction between the two
alleles exists, with a consequent reduction in the frequency of
colon carcinoma development in people carrying this
genotype. If this situation is confirmed in a larger number of
patients and in other tumour types, it could represent an
important model to study at the molecular level.
More information will result from these studies when it is
possible to link the gene structure analyzed here with defined
biological properties; for the present, it is very important
that investigators working on this topic decide on a
standardized approach. In fact, the presently published
studies are very heterogenous: Ha-ras-1 alleles range from 5
or 6 to more than 20 according to different authors, and this
situation makes it very difficult to compare data obtained in
different laboratories.
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